Obesity
Conditions
Interventions
Intervention group:Dosage of the intervention agent: For fermented beverages: 120 - 250 mL
Time: Take it 15 - 30 minutes before meals
Frequency: Once each before lunch and dinner every day.
Control group:Placebos (containing 10% of the intervention agent) are similar to the intervention agent in appearance and odor. Dosage of placebos: 120 - 250 mL
Sponsors
Guilin Tourism University
Eligibility
Sex/Gender
Female
Age
18 Years to 24 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 24 years; 2. Overweight or simply obese individuals with a BMI > 25 kg/m^2 (BMI = weight (kg) ÷ height (m) ÷ height (m)); 3. Volunteers who agree to take the intervention regularly during the trial period; 4. Volunteers who sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Volunteers with endocrine diseases such as hypothyroidism. 2. Volunteers with cardiovascular diseases, such as heart failure, angina, myocardial infarction, and stroke. 3. Volunteers with uncontrolled hypertension, with systolic blood pressure (SBP) > 145 mmHg or diastolic blood pressure (DBP) > 95 mmHg. 4. Volunteers with severe renal or liver impairment (serum creatinine [SCr] > 2.0 mg/dL or alanine transaminase [ALT], aspartate transaminase [AST], and alkaline phosphatase [ALP] levels exceeding 2.5 times the upper limit of normal for liver function). 5. Volunteers with a history of weight loss surgery, such as bariatric surgery. 6. Volunteers with a history or current diagnosis of eating disorders such as anorexia nervosa or bulimia nervosa. 7. Volunteers who have lost more than 10% of their body weight in the past 6 months. 8. Individuals who have decided to quit smoking in the past 3 months or have irregular smoking habits. 9. Volunteers with cholelithiasis (gallstones). 10. Volunteers receiving treatment with controlled substances, including antidepressants, anti-serotonin drugs, barbiturates, antipsychotics, and central nervous system stimulants. 11. Volunteers who have taken any medication in the past 3 months that may affect drug absorption, metabolism, excretion, and weight; these include appetite suppressants, laxatives, oral steroids, thyroid hormones, amphetamines, cyproheptadine, and phenothiazines. 12. Volunteers who are pregnant or of childbearing potential who do not agree to use effective contraception during the study period. 13. Volunteers who have participated in any clinical trial within the past month. 14. Volunteers deemed unable to follow the trial instructions of the clinical trial investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight;Triglycerides;Cholesterol;Low-Density Lipoprotein;High-Density Lipoprotein;Blood Glucose; | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin;Glycated Hemoglobin;Alanine Aminotransferase;Aspartate Aminotransferase;Bilirubin;Uric Acid;Creatinine;Gut Microbiota; | — |
Countries
China
Contacts
Public ContactYan Xiantao
Guilin Tourism University
Outcome results
None listed